×
About 418 results

ALLMedicine™ T Cell Lymphomas Center

Research & Reviews  157 results

Development of a Novel Anti-Mouse CCR4 Monoclonal Antibody (C4Mab-1) by N-Terminal Pept...
https://doi.org/10.1089/mab.2021.0064
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy; Takei J, Suzuki H et. al.

Apr 27th, 2022 - The CC chemokine receptor type-4 (CCR4) belongs to the G-protein-coupled receptor superfamily, expressed on the cell surface of T cells and its malignancy. Two CCR4 ligands (CCL17 and CCL22) bind to CCR4 that mediate physiological and pathological...

"Knock Me Out": The Challenges of Managing Pain Due to Cutaneous T Cell Lymphomas: A Ca...
https://doi.org/10.1089/jpm.2021.0561
Journal of Palliative Medicine; Pandey S, Dolan A et. al.

Apr 15th, 2022 - Cutaneous T cell lymphomas are associated with distressing symptoms, including pain and pruritus that negatively impact quality of life. Early involvement of palliative care can provide relief of symptoms and address multifaceted distress. This ca...

Single-cell analysis of Sézary syndrome reveals novel markers and shifting gene profile...
https://doi.org/10.1182/bloodadvances.2021005991
Blood Advances; Borcherding N, Severson KJ et. al.

Apr 8th, 2022 - Cutaneous T cell lymphomas (CTCLs) are a spectrum of diseases with varied clinical courses caused by malignant clonal proliferation of skin-tropic T cells. Most patients have an indolent disease course managed with skin-directed therapies. In cont...

Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective s...
https://doi.org/10.1111/dth.15482
Dermatologic Therapy; Di Raimondo C, Vaccarini S et. al.

Apr 5th, 2022 - The aim of our retrospective study was to evaluate the efficacy of a continuous therapy with a lower dosage of gemcitabine compared to those usually administered in patients with cutaneous T cell lymphomas (CTCL). Twenty-two patients received diff...

Alcohol-driven metabolic reprogramming promotes development of RORγt-deficient thymic l...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018612
Oncogene Sun R, Lei C et. al.

Mar 6th, 2022 - RORγt is a master regulator of Th17 cells. Despite evidence linking RORγt deficiency/inhibition with metastatic thymic T cell lymphomas, the role of RORγt in lymphoma metabolism is unknown. Chronic alcohol consumption plays a causal role in many h...

see more →

Clinicaltrials.gov  8 results

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT03905135

Feb 3rd, 2022 - Background: Mature T-cell cancers are a phenotypically heterogeneous group of malignancies which constitute 10-15% of all non-Hodgkin lymphomas (NHL). Patients with relapsed/refractory T cell lymphomas have limited therapeutic options, making new ...

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05186012

Jan 11th, 2022 - This is an open-label, multi-center Phase Ib/II study of safety, PK, PD and efficacy of APG-1252 as a single agent in relapsed/refractory NHL or in combination with chidamide in relapsed/refractory peripheral T cell lymphomas (PTCL) patients. The ...

Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial
https://clinicaltrials.gov/ct2/show/NCT02256462

Sep 28th, 2021 - The efficacy of adalimumab in inducing and maintaining remission in both adults and children with moderate-to-severe Crohn's Disease has been demonstrated in multiple clinical trials. Despite efforts to optimize treatment, approximately 40% of pat...

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT04162340

May 19th, 2021 - CD4-specific CAR is a chimeric antigen receptor immunotherapy treatment designed to treat lymphoma/leukemia expressing CD4 antigen. CD4+ T cell lymphomas are a subset of leukemias and lymphomas that are positive for the surface protein CD4. The pu...

Multicenter Analysis of Efficacy and Outcomes of Extracorporeal Photopheresis as Treatment of Chronic Lung Allograft Dysfunction
https://clinicaltrials.gov/ct2/show/NCT04792294

Mar 10th, 2021 - Lung transplantation is an established therapy for end-stage lung disease such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis and pulmonary hypertension. However, Chronic Lung Allograft Dysfunction (CLAD) ...

see more →

News  2 results

Dr. Gascoyne on Predictive Biomarker Research in Lymphomas
https://www.onclive.com/view/dr-gascoyne-on-predictive-biomarker-research-in-lymphomas

Dec 4th, 2020 - Randy Gascoyne, MD, research director, Centre for Lymphoid Cancers at the BC Cancer Agency, discusses the growth of predictive biomarker research in follicular lymphoma and other malignancies. Pertaining to follicular lymphoma, Gascoyne says ther...

Treatment of Cutaneous T-Cell Lymphoma/Mycosis Fungoides
https://www.medscape.com/viewarticle/551357

Abstract and Introduction Abstract Cutaneous T cell lymphomas (CTCL) represent a heterogeneous group of T-cell malignancies that manifest primarily in the skin. By far the most common variant of CTCL is mycosis fungoides and its leukemic variant S...

see more →